Overview
What is AI drug-discovery screening?
AI drug-discovery screening applies machine learning to the earliest, most expensive stages of R&D — predicting which targets are promising, which molecules have the right properties, and which are likely to fail on absorption, distribution, metabolism, excretion, or toxicity (ADMET).
By screening vast chemical space in-silico before committing to wet-lab work, teams focus scarce experimental capacity on the candidates most likely to succeed — reducing costly late-stage attrition and accelerating the path to a viable lead.
What the system analyzes
The Challenge
Most of the cost is spent on molecules that fail
Preclinical discovery is slow, expensive, and dominated by attrition \u2014 most candidates fail before they reach the clinic, often for properties that could have been predicted earlier.
Vast Search Space
Chemical space is effectively infinite; exhaustive wet-lab screening is impossible.
Late-Stage Attrition
Candidates fail late on ADMET and toxicity, after large investment.
Fragmented Knowledge
Insights are scattered across literature, assays, and internal data.
Slow Synthesis Planning
Designing viable synthesis routes is a manual bottleneck.
Education AI Solutions
How Solnix accelerates discovery
Target Identification
Mine omics, literature, and assay data to prioritize promising targets.
Property Prediction
Predict molecular properties to rank candidates in-silico.
ADMET Screening
Flag absorption, metabolism, and toxicity risks early.
Synthesis Planning
Propose viable synthesis routes for promising molecules.
Knowledge Mining
Extract structured insight from literature and internal data.
Prioritization Dashboards
Give research teams a ranked, explainable candidate pipeline.
End-to-End Implementation
How Solnix implements discovery AI
A phased program from data foundation through validated predictive models integrated into research workflows \u2014 measured against your hit-to-lead and attrition metrics.
Discovery & AI Opportunity Mapping
We start by understanding your operations, data landscape, and goals, then map where AI delivers measurable value and where it does not. Every engagement begins with a prioritized opportunity backlog, not a technology pitch.
Data Foundation & Readiness
AI is only as good as the data behind it. We assess data quality, connect fragmented sources, and build the secure, governed pipelines that production AI depends on, with privacy and compliance designed in from the start.
Model & Agent Development
We build the models, retrieval systems, and AI agents tailored to your use cases, selecting the right approach (fine-tuning, RAG, multi-agent orchestration) for accuracy, cost, and latency, and validating against your real-world edge cases.
Integration & Workflow Embedding
AI only creates value when it lives inside the tools your teams already use. We embed models and agents into existing systems, surfaces, and workflows, so adoption is natural and human-in-the-loop controls stay in place.
Deployment, Security & Compliance
We deploy to production with the security, monitoring, and compliance controls enterprises require, including bias and fairness testing, audit logging, and the observability needed to operate AI responsibly at scale.
Optimization & Continuous Improvement
AI systems improve with use. We measure outcomes against the goals set in Phase 01, retrain and tune from live feedback, and expand to the next set of use cases, turning a single deployment into a compounding capability.
Key Capabilities
Key capabilities
Property & ADMET Models
Predict success-determining properties in-silico.
Benefits
Target Discovery
Surface and rank novel targets.
Benefits
Synthesis Planning
Propose feasible routes.
Benefits
Knowledge Extraction
Mine literature and assay data.
Benefits
Explainable Ranking
Show why a molecule ranks.
Benefits
Secure IP Handling
Protect proprietary chemistry.
Benefits
Who Benefits
Outcomes for research, R&D leadership, and the pipeline
For Research Scientists
Focus bench time on the best candidates.
For R&D Leadership
A faster, more predictable pipeline.
For the Pipeline
More shots on goal that count.
Education Segments
Explore related healthcare AI
Clinical Trial Patient Matching
Move winning candidates into faster trials.
Pharmacovigilance
Monitor safety signals post-launch.
Care Gap Identification
Connect therapies to the patients who need them.
Clinical Documentation AI
Ground real-world evidence in structured data.
Enterprise Automation
Automate research operations.
Agent Ecosystem
Orchestrate multi-step research agents.
Methodology
How Solnix builds for healthcare
01, Clinical Workflow Assessment
01, Clinical Workflow Assessment
We shadow real clinical and administrative workflows to design AI around how teams actually work.
02, HIPAA-Compliant Architecture
02, HIPAA-Compliant Architecture
All PHI is processed within HIPAA-compliant infrastructure under signed BAAs, with encryption and access logging.
03, EHR & System Integration
03, EHR & System Integration
We integrate with Epic, Cerner, and Athenahealth via FHIR R4 / HL7 so AI lives inside existing workflows.
04, Clinical Validation
04, Clinical Validation
Systems are validated against retrospective data with clinician oversight before production.
05, Continuous Monitoring
05, Continuous Monitoring
Post-deployment monitoring tracks performance and outcomes; drift triggers retraining.
FAQ
Questions from R&D and informatics leaders
Get Started
Spend Bench Time on Molecules That Win.
Talk to a Solnix specialist about a discovery-screening pilot scoped to your targets, data, and pipeline.
Talk to a Discovery AI Specialist \u2192